Cybin (NASDAQ:HELP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cybin (NASDAQ:HELP – Free Report) from a strong sell rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

HELP has been the topic of several other research reports. Wells Fargo & Company began coverage on Cybin in a research report on Monday, July 27th. They issued an “overweight” rating and a $16.00 price target on the stock. TD Cowen increased their price target on Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Cybin has a consensus rating of “Buy” and an average target price of $48.60.

Get Cybin alerts:

Check Out Our Latest Analysis on HELP

Cybin Stock Performance

Shares of HELP stock opened at $11.76 on Friday. The stock’s 50-day moving average is $8.83 and its two-hundred day moving average is $6.52. Cybin has a 1 year low of $3.76 and a 1 year high of $14.35. The firm has a market cap of $859.19 million, a price-to-earnings ratio of -3.89 and a beta of 0.55.

Cybin (NASDAQ:HELP – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). As a group, research analysts predict that Cybin will post -2.95 EPS for the current year.

Institutional Investors Weigh In On Cybin

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. grew its holdings in shares of Cybin by 46.7% in the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock worth $63,000 after acquiring an additional 2,400 shares during the period. AXQ Capital LP purchased a new position in shares of Cybin in the second quarter valued at $75,000. Bank of America Corp DE increased its position in shares of Cybin by 66.8% in the second quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock valued at $247,000 after buying an additional 11,790 shares in the last quarter. Pale Fire Capital SE acquired a new position in shares of Cybin during the 2nd quarter worth $1,015,000. Finally, Millennium Management LLC boosted its position in shares of Cybin by 1,388.5% in the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after buying an additional 959,448 shares in the last quarter. 17.94% of the stock is currently owned by institutional investors and hedge funds.

Cybin Company Profile

(Get Free Report)

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.

Featured Stories

• Five stocks we like better than Cybin
• Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
• Insiders Are Betting Big on These 3 Healthcare Stocks
• 3 Stocks for Investors Who Still Believe Cash Is King
• Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.